Crescita Therapeutics Inc. (TSE:CTX – Get Rating) Director Anthony Edward Dobranowski purchased 15,638 shares of Crescita Therapeutics stock in a transaction that occurred on Tuesday, August 16th. The stock was bought at an average cost of C$0.69 per share, with a total value of C$10,749.56. Following the completion of the transaction, the director now owns 100,000 shares of the company's stock, valued at C$68,740.
Crescita Therapeutics Price Performance
Shares of CTX opened at C$0.68 on Tuesday. Crescita Therapeutics Inc. has a 1-year low of C$0.55 and a 1-year high of C$0.83. The stock has a market cap of C$14.06 million and a PE ratio of -12.36. The company has a debt-to-equity ratio of 8.58, a current ratio of 3.10 and a quick ratio of 2.23. The firm has a fifty day moving average price of C$0.65 and a 200 day moving average price of C$0.68.
Get
Crescita Therapeutics alerts:
Crescita Therapeutics Company Profile
(Get Rating)
Crescita Therapeutics Inc, a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including MMPE and DuraPeel for the development of topicals containing cannabis and hemp.
See Also
- MarketBeat Podcast: Fantasy Football Strategy With Your Stock Portfolio
- Should You Buy These Copper Stocks Ahead Of Monster Demand?
- Three Industrial Stocks That Can Weather a Stormy Recession
- Bed Bath & Beyond Meat: Is BYND the Next Big Short Squeeze?
- Denbury Rises On Rumor Of A Sale, But Lags Other Energy Names
Receive News & Ratings for Crescita Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crescita Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Crescita Therapeutics Inc. (TSE:CTX – Get Rating) Director Anthony Edward Dobranowski purchased 15,638 shares of Crescita Therapeutics stock in a transaction that occurred on Tuesday, August 16th. The stock was bought at an average cost of C$0.69 per share, with a total value of C$10,749.56. Following the completion of the transaction, the director now owns 100,000 shares of the company's stock, valued at C$68,740.
董事安東尼·愛德華·多布拉諾夫斯基在8月16日星期二的一筆交易中購買了15,638股克雷西塔治療公司的股票。該股是以每股0.69加元的平均成本購買的，總價值為10,749.56加元。交易完成後，董事現在擁有100,000股該公司股票，價值68,740加元。
Crescita Therapeutics Price Performance
Shares of CTX opened at C$0.68 on Tuesday. Crescita Therapeutics Inc. has a 1-year low of C$0.55 and a 1-year high of C$0.83. The stock has a market cap of C$14.06 million and a PE ratio of -12.36. The company has a debt-to-equity ratio of 8.58, a current ratio of 3.10 and a quick ratio of 2.23. The firm has a fifty day moving average price of C$0.65 and a 200 day moving average price of C$0.68.
週二，CTX的股價開盤報0.68加元。Crescita Treateutics Inc.的一年低點為0.55加元，一年高位為0.83加元。該股市值為1406萬加元，市盈率為-12.36倍。該公司的債務權益比為8.58，流動比率為3.10，速動比率為2.23。該公司的50日移動均線價格為0.65加元，200日移動均線價格為0.68加元。
Get
Crescita Therapeutics
alerts:
Crescita Therapeutics Company Profile
Crescita Therapeutics Inc, a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including MMPE and DuraPeel for the development of topicals containing cannabis and hemp.
Cresita治療公司是一家皮膚病公司，在加拿大、美國和國際上提供非處方藥護膚品和處方藥產品。該公司通過三個部門運營：商業護膚品、許可和版税以及製造和服務。它擁有專有平臺技術，包括MMPE和DuraPeel，用於開發含有大麻和大麻的局部藥物。
See Also
- MarketBeat Podcast: Fantasy Football Strategy With Your Stock Portfolio
- Should You Buy These Copper Stocks Ahead Of Monster Demand?
- Three Industrial Stocks That Can Weather a Stormy Recession
- Bed Bath & Beyond Meat: Is BYND the Next Big Short Squeeze?
- Denbury Rises On Rumor Of A Sale, But Lags Other Energy Names
- MarketBeat播客：股票投資組合中的夢幻足球策略
- 你應該在怪物需求之前買入這些銅庫存嗎？
- 三隻能夠渡過風暴般的衰退的工業股票
- 牀上洗澡和肉食之外：Bynd是下一個大空頭嗎？
- Denbury因出售傳言而上漲，但落後於其他能源公司
Receive News & Ratings for Crescita Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crescita Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《克雷西塔治療日報》的新聞和評級-在下面輸入您的電子郵件地址，即可通過MarketBeat.com的免費每日電子郵件時事通訊，收到每日簡明的最新新聞摘要和分析師對克雷西塔治療公司及相關公司的評級。
